Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02816983 · ClinicalTrials.gov registry record
SBRT for Oligometastatic Castration-Refractory Prostate Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 89
- Enrollment target
NCT02816983: Completed study, sponsored by Mayo Clinic.
NCT02816983 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 89 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02816983 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 89 participants
- Enrollment target
Study Summary
Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Blood draws will be taken to monitor the development of anti-prostate cancer immunity
Interventions
- RADIATION SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2016-03 |
| Est. Completion | 2022-01-20 |
What the finished NCT02816983 record still lists
NCT02816983 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SBRT is the first listed.
NCT02816983 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02816983 about?
NCT02816983 is a clinical study titled "SBRT for Oligometastatic Castration-Refractory Prostate Cancer". Castration-resistant prostate cancer patients with rising prostatic specific antigen (PSA) are eligible for this study. 11C-Choline PET/CT will be used to identify metastatic lesions. Patients with \<=3 metastatic lesions will receive stereotactic body radiotherapy (SBRT) as definitive treatment. Bl...
What is the current status of trial NCT02816983?
This trial is currently completed. The enrollment target is 89 participants. The study started on 2016-03. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT02816983?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT02816983?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia